MPP Logo
LinkedIn YouTube Bluesky
Search
English / Français
Ethics Portal
LinkedIn YouTube Bluesky
Search
English / Français
Ethics Portal
  • Who We Are
    • About Us
    • Business Model
    • Our Strategy 2023-2025
    • Statutes, By-Laws & Policies
    • Governance & Team
    • Annual Reports
    • Careers & RFPs
  • What We Do
    • Licensing for Public Health
    • mRNA Technology Transfer Programme
    • Prioritising Medicines for Licensing
    • Disease Areas
    • Focus areas
      • Biotherapeutics
      • Local and Regional Production
      • Pandemic Preparedness and Response
      • Regulatory Access
      • Technology Transfer
      • Upstream Access
    • Addressing Children’s Needs
    • Patent Information Tools
      • MedsPaL
      • LAPaL
    • Long-Acting Therapeutics
  • Progress
    • Prioritisation
    • Licences
    • Access to Medicines Tracker
    • Contribution to Universal Health Coverage
    • Endorsements
    • Impact
  • News & Publications
    • News, Events & Press Releases
    • Messages from the Executive Director
    • MPP in the Media
    • MPP Publications
    • Related Publications
    • Newsletters & Updates
  • Partners
    • Partnering with MPP
    • Our Stories
      • Kenya
      • Ukraine
      • India
      • Voices from Friends of MPP
    • Funders
    • How to Give or Get a Licence
  • Contact Us

Related Publications

Despite considerable progress in paediatric HIV treatment and timely revision of global policies recommending the use of more effective and tolerable antiretroviral regimens, optimal antiretroviral formulations for infants, children, and adolescents remain limited. The Paediatric Antiretroviral Drug Optimization group reviews medium-term and long-term priorities for antiretroviral drug development to guide industry and other stakeholders on formulations most needed for low-income and middle-income countries. The group convened in December, 2018, to assess progress since the previous meeting and update the list of priority formulations. Issues relating to drug optimisation for neonatal prophylaxis and paediatric treatment, and those relating to the investigation of novel antiretrovirals in adolescents and pregnant and lactating women were also discussed. Continued focus on identifying, prioritising, and providing access to optimal antiretroviral formulations suitable for infants, children, and adolescents is key to ensuring that global HIV treatment targets can be met.

news & publications » Related Publications

Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list

11 September 2019

Share page:
Facebook
Linkedin
Bluesky

Contact Us

Press and Media

About Us

The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders, to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.

To date, MPP has signed agreements with 18 patent holders for 14 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, three oral antiviral treatments for COVID-19 and 12 COVID-19 technologies.

MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC). MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, and SDC.

MPP Logo

Subscribe to our Newsletter

Subscribe to our Newsletter

Subscribe

* indicates required






The Medicines Patent Pool will use the information (email address) you provide on this form to be in touch with you and to provide updates.


You can change your mind at any time by clicking the unsubscribe link in the footer of any email you receive from us, or by contacting us at press@medicinespatentpool.org. We will treat your information with respect. For more information about our privacy practices, please visit our website. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp’s privacy practices here.


About Us
Licences
MedsPaL
Careers & RFPs
Contact

Founded & funded by

Unitaid Logo

Other funders